Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa

Ophthalmic Plastic and Reconstructive Surgery

Volumn 19, Issue 4, 2003, Pages 305-308

  Esmaeli, Bita ^a   Burnstine, Michael A ^b   Ahmadi, M Amir ^a   Prieto, Victor G ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; EPIPHORA; EPISTAXIS; FEMALE; HISTOPATHOLOGY; HUMAN; LACRIMAL SAC; NOSE MUCOSA; PRIORITY JOURNAL;

EID: 0041306111     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.IOP.0000075016.29682.E0     Document Type: Article

References (13)

1. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
2. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
3. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-8.
4. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999;26:32-6.
5. Burstein HJ, Manola, J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9.
6. Esmaeli B, Valero V, Ahmadi MA, et al. Canalicular stenosis secondary to docetaxel (Taxotere): a newly recognized side effect. Ophthalmology 2001;108:994-5.
7. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canalicular stenosis secondary to weekly versus every-three-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002;109:1188-91.
8. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving weekly docetaxel. Arch Ophthalmol 2001;119:1802-4.
9. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002;13:218-21.
10. Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002;120:1180-2.
11. Haidak DJ, Hurwitz BS, Yeung BS. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978;88:657.
12. Lee V, Bentley CR, Olver JM. Sclerosis canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye 1998;12:343-9.
13. Fezza JP, Wesley RE, Klippenstein KA. The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. Ophthal Surg Lasers 1999;30:105-8.